Noom Data Shows Higher Engagement Tied to Better GLP-1 Outcomes
Event summary
- Noom's analysis of 14,203 GLP-1Rx Program members found top-quartile app users lost 25.2% more weight (8.3 lbs) by week 40 than bottom-quartile users.
- Highly engaged members stayed on GLP-1 medication programs 2.2x longer than less-engaged peers.
- Noom's GLP-1 Companion app, launched in November 2023, now includes features like AI food logging, medication tracking, and body composition scans.
- 40% of Noom Microdose members used the app daily, a retention rate 10x higher than average for digital health apps.
The big picture
Noom's findings highlight the growing intersection of digital behavior change tools and pharmaceutical treatments, particularly in weight management. The data suggests that engagement-driven platforms could become critical differentiators in the GLP-1 market, where medication adherence and sustained behavior change are key to long-term success. This aligns with broader industry trends toward personalized, tech-enabled healthcare solutions that combine medication with behavioral support.
What we're watching
- Product Differentiation
- Whether Noom's engagement-driven outcomes can sustain competitive advantage as GLP-1 market matures.
- Revenue Model
- How Noom monetizes higher engagement and longer medication persistence through its subscription programs.
- Regulatory Scrutiny
- The pace at which health authorities may examine claims linking digital engagement to medical outcomes.
Related topics